跳至主要内容
临床试验/CTRI/2024/03/064730
CTRI/2024/03/064730招募中不适用

A Multi-centric Performance Evaluation of Diagnostic Accuracy of Determineâ„¢ TB LAM Ag Test, a Point-of-Care Urine Lipoarabinomannan Assay, for detection of Active Tuberculosis in People Living with HIV in India

Abbott Diagnostics Medical Pvt Ltd5 个研究点 分布在 1 个国家目标入组 330 人开始时间: 2024年3月30日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
330
试验地点
5
主要终点
Diagnostic performance evaluation of Determine TB LAM Ag Test

研究概览

简要总结

A Multi-centric Evaluation of Diagnostic Accuracy of Determineâ„¢ TB LAM Ag Test, a Point-of-Care Urine Lipoarabinomannan Assay, for detection of Active Tuberculosis in People Living with HIV in India.

The Determineâ„¢ TB LAM Ag Test is an in vitro, point-of-care, visually read, qualitative immunoassay for the detection of Lipoarabinomannan (LAM) antigen of Mycobacteria in human urine as an aid in the diagnosis of active TB disease. It is a urine test kit, results of which are visually read as positive or negative depending on visibility or non-visibility of a purple/ grey line, which is indicative of level of LAM antigen of Mycobacteria present in the sample.

Objective of Study  - The aim of the study is to evaluate the diagnostic accuracy of the Determineâ„¢ TB LAM Ag Test, a point-of-Care urinary LAM assay, for detection of active TB disease in people living with HIV (PLHIV) with CD4 counts less than or equal to 200 cells/mm3in India.

The study has been approved by CDSCO and Expert Committee on 1st Mar 2024

研究设计

研究类型
Interventional
分配方式
Na
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 80.00 Year(s)(—)
性别
All

入选标准

  • HIV positive status and CD4 count ≤ 200 cells/ mm3.

排除标准

  • Individual currently under anti-tuberculosis treatment (ATT).

结局指标

主要结局

Diagnostic performance evaluation of Determine TB LAM Ag Test

时间窗: This is approximately 12 months study for enrolling 330 patients which we expect to start from 1st of April 2024 and complete on or before Mar 2025 and result analysis will be done within Mar/Apr 2025

次要结局

  • A point-of-Care urinary LAM assay, for detection of active TB disease in people living with HIV (PLHIV) with CD4 counts less than or equal to 200 cells/mm in India(This is approximately 12 months study for enrolling 330 patients which we expect to start from 1st of April 2024 & complete on or before Mar 2025 & result analysis will be done within Mar/Apr 2025)

研究者

发起方
Abbott Diagnostics Medical Pvt Ltd
申办方类型
Pharmaceutical industry-Global
责任方
Principal Investigator
主要研究者

Dr Upasna Agarwal

National Institute Of Tuberculosis and Respiratory Diseases

研究点 (5)

Loading locations...

相似试验